CBAK Energy Technology, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that CBAK Energy Technology, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $195.19M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $176.61M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $204.44M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $248.73M | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | $52.67M | Apr 14, 2023 |
| FY2021 | Dec 31, 2020 | $37.57M | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | $22.19M | Apr 13, 2021 |
| FY2019 | Dec 31, 2018 | $24.43M | May 14, 2020 |
| FY2018 | Dec 31, 2017 | $58.38M | Apr 16, 2019 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $58.38M | Apr 17, 2018 |
| FY2017 | Dec 31, 2016 | $3.50M | Apr 17, 2018 |
| FY2017 | Sep 30, 2016 | $10.37M | Apr 17, 2018 |
| FY2016 | Sep 30, 2015 | $13.90M | Jan 13, 2017 |
| FY2015 | Sep 30, 2014 | $123.01M | Jan 13, 2016 |
| FY2014 | Sep 30, 2013 | $185.55M | Jan 13, 2015 |
| FY2013 | Sep 30, 2012 | $205.52M | Jan 14, 2014 |
| FY2012 | Sep 30, 2011 | $218.95M | Dec 31, 2012 |
| FY2011 | Sep 30, 2010 | $214.80M | Dec 14, 2011 |
| FY2011 | Sep 30, 2009 | $211.14M | Dec 14, 2011 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $18.42M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $41.78M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $31.72M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $18.10M | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | $5.11M | Apr 14, 2023 |
| FY2021 | Dec 31, 2020 | $2.71M | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | $622.5K | Apr 13, 2021 |
| FY2019 | Dec 31, 2018 | ($3.30M) | May 14, 2020 |
| FY2018 | Dec 31, 2017 | ($10.20M) | Apr 16, 2019 |
| FY2017 | Dec 31, 2016 | ($474.1K) | Apr 17, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($9.38M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $11.79M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($2.45M) | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | ($9.45M) | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | $61.49M | Apr 14, 2023 |
| FY2021 | Dec 31, 2020 | ($7.85M) | Apr 15, 2022 |
| FY2019 | Dec 31, 2019 | ($10.77M) | May 14, 2020 |
| FY2019 | Dec 31, 2018 | ($1.94M) | May 14, 2020 |
| FY2018 | Dec 31, 2017 | ($21.47M) | Apr 16, 2019 |
| FY2017 | Dec 31, 2016 | ($2.19M) | Apr 17, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($18.44M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $8.79M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($7.25M) | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | ($11.50M) | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | ($11.71M) | Apr 14, 2023 |
| FY2021 | Dec 31, 2020 | ($8.48M) | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | ($10.09M) | Apr 13, 2021 |
| FY2019 | Dec 31, 2018 | ($13.44M) | May 14, 2020 |
| FY2018 | Dec 31, 2017 | ($21.18M) | Apr 16, 2019 |
| FY2017 | Dec 31, 2016 | ($2.24M) | Apr 17, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $15.80M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $13.01M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $11.93M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $10.64M | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | $5.27M | Apr 14, 2023 |
| FY2021 | Dec 31, 2020 | $1.68M | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | $1.91M | Apr 13, 2021 |
| FY2019 | Dec 31, 2018 | $2.48M | May 14, 2020 |
| FY2018 | Dec 31, 2017 | $1.74M | Apr 16, 2019 |
| FY2017 | Dec 31, 2016 | $439.0K | Apr 17, 2018 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $1.50M | Apr 15, 2022 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $48.55M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $39.70M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $46.51M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $15.11M | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | ($4.27M) | Apr 14, 2023 |
| FY2021 | Dec 31, 2020 | ($5.10M) | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | ($21.22M) | Apr 13, 2021 |
| FY2019 | Dec 31, 2018 | $8.73M | May 14, 2020 |
| FY2018 | Dec 31, 2017 | $6.22M | Apr 16, 2019 |
| FY2017 | Dec 31, 2016 | ($6.32M) | Apr 17, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $44.65M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $17.19M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $31.14M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $12.37M | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | $19.21M | Apr 14, 2023 |
| FY2021 | Dec 31, 2020 | $5.71M | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | $2.45M | Apr 13, 2021 |
| FY2019 | Dec 31, 2018 | $7.36M | May 14, 2020 |
| FY2018 | Dec 31, 2017 | $12.05M | Apr 16, 2019 |
| FY2017 | Dec 31, 2016 | $1.67M | Apr 17, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $426.18M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $302.22M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $281.16M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $244.03M | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | $262.62M | Apr 14, 2023 |
| FY2021 | Dec 31, 2020 | $142.77M | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | $95.58M | Apr 13, 2021 |
| FY2019 | Dec 31, 2018 | $127.58M | May 14, 2020 |
| FY2018 | Dec 31, 2017 | $153.13M | Apr 16, 2019 |
| FY2017 | Dec 31, 2016 | $92.11M | Apr 17, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $316.70M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $182.15M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $167.70M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $119.65M | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | $121.73M | Apr 14, 2023 |
| FY2021 | Dec 31, 2020 | $90.36M | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | $81.93M | Apr 13, 2021 |
| FY2019 | Dec 31, 2018 | $127.26M | May 14, 2020 |
| FY2018 | Dec 31, 2017 | $150.94M | Apr 16, 2019 |
| FY2017 | Dec 31, 2016 | $79.44M | Apr 17, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $112.68M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $121.67M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $112.82M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $117.50M | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | $133.29M | Apr 14, 2023 |
| FY2021 | Dec 31, 2020 | $52.40M | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | $13.61M | Apr 13, 2021 |
| FY2019 | Dec 31, 2018 | $315.3K | May 14, 2020 |
| FY2018 | Dec 31, 2017 | $2.20M | Apr 16, 2019 |
| FY2017 | Dec 31, 2016 | $12.68M | Apr 17, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2021 | $1.65M | Mar 15, 2024 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($133.80M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($122.61M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($134.40M) | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | ($131.95M) | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | ($122.50M) | Apr 14, 2023 |
| FY2021 | Dec 31, 2020 | ($183.98M) | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | ($176.18M) | Apr 13, 2021 |
| FY2019 | Dec 31, 2018 | ($165.41M) | May 14, 2020 |
| FY2018 | Dec 31, 2017 | ($163.47M) | Apr 16, 2019 |
| FY2017 | Dec 31, 2016 | ($142.00M) | Apr 17, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.30M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $6.72M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $4.64M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $6.52M | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | $7.36M | Apr 14, 2023 |
| FY2021 | Dec 31, 2020 | $11.68M | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | $1.61M | Apr 13, 2021 |
| FY2019 | Dec 31, 2018 | $449.7K | May 14, 2020 |
| FY2018 | Dec 31, 2017 | $1.64M | Apr 16, 2019 |
| FY2017 | Dec 31, 2016 | $408.7K | Apr 17, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.12M | Mar 31, 2026 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Apr 14, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | 0 | Apr 13, 2021 |
| FY2019 | Dec 31, 2018 | 0 | May 14, 2020 |
| FY2016 | Sep 30, 2016 | 0 | Jan 13, 2017 |
| FY2016 | Sep 30, 2015 | 1 | Jan 13, 2017 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Apr 14, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Apr 15, 2022 |
| FY2017 | Dec 31, 2017 | 0 | Apr 17, 2018 |
| FY2017 | Dec 31, 2016 | 0 | Apr 17, 2018 |
| FY2017 | Sep 30, 2016 | 0 | Apr 17, 2018 |
| FY2016 | Sep 30, 2015 | 1 | Jan 13, 2017 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 88.65M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 89.94M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 89.92M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | 88.99M | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | 88.71M | Apr 14, 2023 |
| FY2021 | Dec 31, 2020 | 79.17M | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | 53.08M | Apr 13, 2021 |
| FY2019 | Sep 30, 2019 | 44.18M | May 14, 2020 |
| FY2019 | Dec 31, 2018 | 26.65M | May 14, 2020 |
| FY2018 | Dec 31, 2017 | 26.22M | Apr 16, 2019 |